Emergent BioSolutions Inc. / EBS
About Emergent BioSolutions Inc.
2273 Research Blvd., Suite 400, Rockville, Md. 20850
www.emergentbiosolutions.com
| 301-795-1800
| Founded: 1998
Industry: Biotechnology | Category: Top 100 Companies
Emergent BioSolutions went public in November, raising $52.4 million. Not long after, the federal government canceled a $877.5 million contract with VaxGen, which was supposed to have provided 75 million doses of a new-generation anthrax vaccine for the national stockpile.
The government has bought 10 million doses of Emergent's vaccine for the stockpile, but the cancellation of the VaxGen contract leaves a hole in the government's efforts against anthrax, one that Emergent would like to fill. The problem with Emergent's vaccine, however, is that it requires as many as six doses; the government wants fewer. So Emergent is testing a new version of the vaccine that uses an adjuvant, or additive, to help enhance the vaccine and speed its ability to boost immune response in the body.
2007 Financial Data
Total employees: 470 | Local employees: 150Company Leadership
| Fuad El-Hibri | Chairman and CEO |
Source: Compensation data provided by Equilar, Inc..
Did You Know
Emergent BioSolutions Inc. makes the only federally approved anthrax vaccine. The company is also working on vaccines for typhoid and hepatitis B. Its primary market is in biodefense, an industry that has received a lot of attention since the anthrax attacks a few years ago.
